Alkem Laboratories Ltd banner

Alkem Laboratories Ltd
NSE:ALKEM

Watchlist Manager
Alkem Laboratories Ltd Logo
Alkem Laboratories Ltd
NSE:ALKEM
Watchlist
Price: 5 400 INR 1.05% Market Closed
Market Cap: ₹645.6B

EV/FCFF

57.8
Current
40%
More Expensive
vs 3-y average of 41.3

Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.

EV/FCFF
57.8
=
Enterprise Value
₹624.1B
/
Free Cash Flow to Firm
₹10.4B

Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.

EV/FCFF
57.8
=
Enterprise Value
₹624.1B
/
Free Cash Flow to Firm
₹10.4B

Valuation Scenarios

Alkem Laboratories Ltd is trading above its 3-year average

If EV/FCFF returns to its 3-Year Average (41.3), the stock would be worth ₹3 861.62 (28% downside from current price).

Statistics
Positive Scenarios
0/4
Maximum Downside
-38%
Maximum Upside
No Upside Scenarios
Average Downside
28%
Scenario EV/FCFF Value Implied Price Upside/Downside
Current Multiple 57.8 ₹5 400
0%
3-Year Average 41.3 ₹3 861.62
-28%
5-Year Average 41.1 ₹3 843.08
-29%
Industry Average 47.3 ₹4 423.09
-18%
Country Average 35.9 ₹3 354.43
-38%

Forward EV/FCFF
Today’s price vs future free cash flow to firm

Not enough data available to calculate forward EV/FCFF

Peer Comparison

All Multiples
EV/FCFF
P/E
All Countries
Close
Market Cap EV/FCFF P/E
IN
Alkem Laboratories Ltd
NSE:ALKEM
645.7B INR 57.8 27.2
US
Eli Lilly and Co
NYSE:LLY
910.2B USD 158.2 44.1
US
Johnson & Johnson
NYSE:JNJ
547.1B USD 29.1 26
CH
Roche Holding AG
SIX:ROG
248.4B CHF 26.4 20.1
UK
AstraZeneca PLC
LSE:AZN
209.6B GBP 39.6 27.4
CH
Novartis AG
SIX:NOVN
221.1B CHF 19.6 20.7
US
Merck & Co Inc
NYSE:MRK
277.6B USD 25.1 15.2
IE
Endo International PLC
LSE:0Y5F
244.4B USD 1 486.8 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.2T DKK 45.7 12.1
US
Pfizer Inc
NYSE:PFE
149.7B USD 21.8 19.3
US
Bristol-Myers Squibb Co
NYSE:BMY
117.2B USD 11.7 16.6
P/E Multiple
Earnings Growth PEG
IN
Alkem Laboratories Ltd
NSE:ALKEM
Average P/E: 22.9
27.2
7%
3.9
US
Eli Lilly and Co
NYSE:LLY
44.1
32%
1.4
US
Johnson & Johnson
NYSE:JNJ
26
8%
3.3
CH
Roche Holding AG
SIX:ROG
20.1
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
27.4
25%
1.1
CH
Novartis AG
SIX:NOVN
20.7
14%
1.5
US
Merck & Co Inc
NYSE:MRK
15.2
14%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
12.1
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.3
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.6
16%
1

Market Distribution

In line with most companies in India
Percentile
67th
Based on 1 703 companies
67th percentile
57.8
Low
0.1 — 20.7
Typical Range
20.7 — 64.8
High
64.8 —
Distribution Statistics
India
Min 0.1
30th Percentile 20.7
Median 35.9
70th Percentile 64.8
Max 50 585.9

Alkem Laboratories Ltd
Glance View

Alkem Laboratories Ltd., founded in 1973, has emerged as a significant player in India's pharmaceutical landscape, deftly combining innovation with a robust distribution network. Anchored in Mumbai, Alkem began as a modest venture but quickly evolved into a powerhouse, renowned for manufacturing a broad spectrum of branded generics, over-the-counter products, and active pharmaceutical ingredients (APIs). The company's success lies in its ability to cater to both domestic and international markets, primarily thriving on the ever-increasing demand for affordable healthcare solutions. Its formidable market presence in India is supported by a strong sales force and an extensive distribution network, ensuring its therapies reach even the most remote corners of the country. Internationally, Alkem has carved a niche for itself, with the United States being one of its major export markets. It strategically entered this competitive arena, building a portfolio of ANDAs (Abbreviated New Drug Applications) that allowed it to provide lower-cost alternatives to big pharma's patented drugs. This not only fueled its revenue growth but also fortified its standing as a go-to source for quality generics. Alkem's research and development efforts underpin its commitment to healthcare innovation, as it constantly seeks to expand its therapeutic repertoire. By consistently focusing on quality, affordability, and resourceful adaptation to global healthcare needs, Alkem Laboratories Ltd. has managed to script a growth story that is both impressive and sustainable.

ALKEM Intrinsic Value
4 218.11 INR
Overvaluation 22%
Intrinsic Value
Price ₹5 400
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett